These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 5076123)

  • 1. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
    Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
    Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical tests using pyridinol carbamate on the arterial circulation and blood coagulation in patients with arteriosclerosis obliterans].
    De Soldati L; Castro CM; Grilli H; Reussi J
    Prensa Med Argent; 1969 May; 56(12):546-53. PubMed ID: 5343928
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anginin (pyridinol carbamate) therapy of coronary atherosclerosis and obliterating atherosclerosis of the arteries of the lower extremities].
    Liusov VA; Belousov IuB; Martynov AI; Koroleva SA; Zimin VS
    Kardiologiia; 1972 Nov; 12(11):39-45. PubMed ID: 4655879
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 5. [Controlled experimental study of the relations between fibrinolytic acitivity and anticoagulant activity in evaluation of activators of fibrinolysis].
    Cascone A; Lampugnani P
    Minerva Med; 1969 Dec; 60(99 Suppl):5039-45. PubMed ID: 4188588
    [No Abstract]   [Full Text] [Related]  

  • 6. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
    Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
    Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of atherosclerosis by pyridinolcarbamate. Review of the history of the introduction of pyridinolcarbamate and its clinical results].
    Shimamoto T
    Rev Atheroscler (Paris); 1968; 10(3):67-84. PubMed ID: 5746502
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
    Atsumi T; Motomiya T; Isokane N; Shimamoto T
    Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of various drugs on the dynamics of fibrinolysis in humans].
    Brunetti S; Tesi M
    Riv Crit Clin Med; 1967 Aug; 67(3):233-45. PubMed ID: 5633715
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of urokinase, pyridinolcarbamate, and dypiridamole in rat heart allografts.
    Ono K; Hattori T; Inokuchi K
    Surgery; 1973 Jan; 73(1):128-32. PubMed ID: 4566777
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
    Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
    Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
    Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
    Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of pyridinol carbamate (Anginin) in peripheral arterial blood circulation disorders].
    Heisig N; Westermann KW; Stolterfoht CA; Zaki J
    Med Klin; 1970 Dec; 65(52):2289-93. PubMed ID: 5522670
    [No Abstract]   [Full Text] [Related]  

  • 15. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of long-term pentoxifylline treatment on selected parameters of the fibrinolytic system in patients with arteriosclerosis obliterans of the legs].
    Berent H; Kancelarczyk WL; Zebrowski M; Uchman B
    Pol Tyg Lek; 1988 Jun; 43(24):776-8. PubMed ID: 3237518
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
    Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
    Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
    [No Abstract]   [Full Text] [Related]  

  • 19. [Modifications of fibrinolysis and coagulation activity in arteriosclerotic patients treated with a polysulfoester of pentosan (SP-54). I].
    Cajozzo A; Citarrella P; Malleo C
    Boll Soc Ital Cardiol; 1971; 16(3):117-26. PubMed ID: 4110180
    [No Abstract]   [Full Text] [Related]  

  • 20. [A double blind crossover trial in pyridinolcarbamate treatment of atherosclerosis obliterans].
    Yamashita S
    Nihon Naika Gakkai Zasshi; 1969 Apr; 58(4):283-92. PubMed ID: 4896659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.